6:30 am – 5:15 pm
Registration Open
GrandeFoyer
7:00 – 8:00 am
Product Theater | Lilly USA,LLC
Continental Breakfast Served (First come first serve, Limited to 100)
A Closer Look at Taltz
Margret Bobonich, CNP, DNP
Commercial Support Provided by Lilly USA, LLC
Nautilus 1 & 2
7:00 – 8:00 am
Product Theater | Pfizer, Inc.
Continental Breakfast Served (First come first serve, Limited to 100)
Novel Nonsteroidal Topical Prescription for Mild-to-Moderate Atopic Dermatitis
Adelaide Hebert, MD
Commercial Support Provided by Pfizer, Inc.
Nautilus 3 & 4
General Session 201
8:00 – 9:00 am
Psoriasis Comorbidities: An Evidence-Based Overview – AANP
Lakshi Aldredge, MSN, ANP-BC
Psoriasis was initially believed a skin disorder of keratinocyte hyperproliferation. Today, there is ample scientific evidence that psoriasis affects numerous systems resulting in significant comorbidities that impact overall health and quality of life. Dermatology nurses need to be aware of these comorbidities in order to provide evidence-based, accurate patient education that can impact selection of psoriasis treatments.
Learning Objectives:
1 – Identify 8 comorbidities associated with psoriatic disease.
2 – Describe most common pharmacologic treatments used in management of the conditions.
Grande Ballroom B/C
General Session 3
9:15 – 10:45 AM
Exhibits Open
Coffee Service
Pavilion
Session 211
10:45 – 11:45 AM
The Research Team in Dermatology – AANP
Eric Smith, MST, MBA
The purpose of this workshop will be to introduce dermatology clinical professionals to the collateral field of clinical research. Topics will include a brief overview and history of clinical research, associated regulations encountered in running a trial, and an overview of the drug development pipeline. Special consideration will be given to the role of the research nurse in a clinical trials unit, including expectations, responsibilities, and rewards, as well as how to pursue a career in Clinical Research Nursing. Time will be allotted for Q&A.
Learning Objectives:
1 – Describe the background, regulations and processes involved in conducting clinical trials.
2 – Apply this knowledge to the dermatology clinic.
Nautilus 1&2
Concurrent Session
Session 212
10:45 – 11:45 AM
MA Forum
Sarah Neider, MA
The presentation will begin with a lecture titled, “Prior Authorizations, Step Therapy, Quantity Limits: What Does It All Mean?” followed by an audience participation based open forum for medical assistants to discuss their roles and responsibilities in a clinical setting, identify professional challenges and review opportunities for growth within the DNA.
Learning Objective:
1 – To provide an overview on prior authorizations, step therapy and quantity limitations to the dermatology clinical team member in order to increase efficiency and patient care.
2 – To provide a forum at Convention for medical assistants within the DNA to meet, network and discuss relevant issues within their profession.
Nautilus 5
Concurrent Session
Session 213
10:45 – 11:45 AM
Case Study: Mortality from Mismanagement of Skin Infection – AANP
Beth Haney, DNP, FNP-C, FAANP
This presentation will walk the attendee through a case study where clinical mistakes and omissions made by multiple providers ended in the death of a child.
Learning Objectives:
1 – Identify appropriate treatment regimens for skin infections.
2 – Describe some adverse reactions that can occur with antibiotic use.
3 – Avoid misuse of antibiotics when caring for a patient with skin infections.
Grande Ballroom A
Concurrent Session
11:45 am – 1:00 pm
Luncheon Theater (All are invited)
Sponsored by Amgen
A Treatment Option for Moderate to Severe Pediatric Plaque Psoriasis
Speaker – Lisa Swanson, MD
Grande Ballroom B/C
Session 221
1:00 – 2:00 PM
Cutaneous Lymphomas: Intersecting Clinical Care and Community, Part II – AANP
Marianne Tawa, MSN, RN, ANP
Susan McCann, MSN, RN, DNC
This cutting edge Part I/II presentation series will introduce and carry the audience through the world of cutaneous T and B cell lymphomas. Learners will gather critical tips on assessment and diagnosis of patients suspected of cutaneous lymphoproliferative malignancy. Implementing and managing patients exposed to skin directed treatment options such as, topical corticosteroids, nitrogen mustard, phototherapy, and radiation will become strategic. A brief overview of systemic therapies will be included. Select case studies will be incorporated to solidify the teaching points. The ever so vital role of community engagement and advocacy in rare diseases such as CTCL and Cutaneous B cell Lymphoma will be intertwined.
Learning Objectives:
1 – Describe the physical examination features and symptom complex associated with patch/plaque/tumor/erythroderma associated with CTCL.
2 – Identify 2 key indications for delivery of skin directed and systemic therapies in patients with persistent/progressive CTCL, elaborating safety monitoring requirements.
3 – Identify educational and advocacy resources for the CTCL patient population.
Nautilus 1&2
Concurrent Session
Session 222
1:00 – 2:00 PM
The Other Side of Mohs Surgery: The Laboratory Technician’s Perspective – AANP
Eric Smith, MST, MBA
The purpose of this workshop is to introduce the dermatology clinical professional to the work of their partners in the Mohs lab. Discussion will include the history of Mohs, the current ‘state-of-the-art’ processes, limited description of some of the challenges faced, and ways that the clinical staff can integrate into the lab.
Learning Objective:
1 – Describe the laboratory-based background, regulations, and processes involved in conducting Mohs Surgery.
Nautilus 5
Concurrent Session
Session 223
1:00 – 2:00 PM
Aesthetic Treatment Updates: Advances in Cosmetic Dermatology – AANP
Beth Haney, DNP, FNP-C, FAANP
This presentation will provide information on FDA approved aesthetic treatments, analysis of the aging face, and determining how different treatments would help different concerns of the patient. This talk is geared for the practitioner who is interested in learning about aesthetic treatments and will serve as an introduction to the latest procedures.
Learning Objectives:
1 – Describe appropriate treatment options for the aging face.
2 – Identify the dosage, pharmacokinetics, application and treatment using fillers and neuromodulators as well as potential complications associated with them.
3 – Describe the use of phototherapy and blue light treatments.
Grande Ballroom A
Concurrent Session
2:00 – 3:00 pm
Exhibits Open/Poster Viewing
Pavilion
Session 231
3:00 – 4:00 PM
Fun in the Sun: The Use of Sunscreen on a College Campus
Katreena Collette-Merrill,PhD, RN
Emily Graham, LPN
Findings will be presented that were gathered from a study at the College of Nursing at Brigham Young University to increase college students understanding of skin cancer and sun protection.
Learning Objective:
1 – Describe the Fitzpatrick Skin Scale and the importance of sunscreen to prevent UV damage.
Nautilus 1&2
Concurrent Session
Session 232
3:00 – 4:00 PM
Update on Melanoma – AANP
Oliver Wisco, DO, FAAD, FACMS
Learning Objectives:
1 – Describe the impact of the new Melanoma NCCN guideline and AJCC staging criteria on surgery for melanoma.
2 – Apply the current treatment concepts for melanoma.
3 – Identify the surgical approach to early stage melanoma.
Grande Ballroom A
Concurrent Session
Session 233
3:00 – 4:00 PM
Hidradenitis Suppurativa and Use of CO2 Laser for Treatment – AANP
Nicole VanHaaren BSN, BBA, RN
Sherri Minchella BBA, ADN, RN
A Hidradenitis Suppurativa (HS) patient’s initial experience usually happens outside dermatology causing a delay in diagnosis by an average of seven years. During the seven year delay many of our patients experience depression, embarrassment and progression of the disease due to misdiagnosis leading to poor inadequate care. HS is a chronic, non-contagious, painful and debilitating inflammatory skin disease affecting 1-4% of the global population. Most commonly found in skin folds, producing deep-seated follicular papules and pustules. Our goal is to promote HS awareness through education and patient support. Creating timely diagnosis we can improve patient care and patient quality of life.
Learning Objectives:
1 – Identify the manifestations, diagnosis, comorbidities and stages of Hidradenitis Suppurativa (HS).
2 – Describe the 1st, 2nd and 3rd line treatment options to manage HS, explaining the pharmacokinetics, dosing, potential adverse reactions and method of delivery for each.
3 – Consider the psychological and emotional aspects of the patient and family.
4 – Educate patient on the use of CO2 Laser surgery as a treatment including pre and post op care.
Nautilus 5
Concurrent Session
General Session 240
4:00 – 5:00 PM
Practical Dermoscopy – AANP
Caroline Kim, MD
Practical pearls and dermoscopy algorithms will be reviewed for both melanocytic and non-melanocytic lesions to help clinicians use their dermatoscope to distinguish benign from malignant lesions.
Learning Objectives:
1 – Evaluate the use of dermoscopy to diagnose melanocytic and non-melanocytic lesions, both benign and malignant.
2 – Recognize the patterns of malignant vs benign cells under dermoscopy.
3 – Limit the number of unnecessary biopsies by properly interpreting results from dermoscopy.
Grande Ballroom B/C
General Session 4